Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97185885

Filing Date: 12/22/2021

To the Commissioner for Trademarks:

MARK: Telocel (Standard Characters, see mark)
The literal element of the mark consists of Telocel. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Seragon Pharmaceuticals Inc., a corporation of Wyoming, having an address of
      400 Spectrum Center Dr., Ste. 1600
      Irvine, California 92618
      United States
      858-366-9100(phone)
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical and biological preparations for immunotherapy, including cell therapy and gene therapy; pharmaceutical and biological preparations for medical diagnostic use; pharmaceutical and biological preparations for medical use, namely, for the prevention and treatment of diseases and disorders of the nervous system, the immune system and the cardiovascular system, the metabolic system, the endocrine system, the respiratory system, the musculo-skeletal system and the genitourinary system, and for the treatment of inflammatory diseases and disorders; pharmaceutical and biological preparations for medical use, namely, for use in dermatology, oncology, hematology and in tissue and organ transplantation in ophthalmology and for gastroenterological diseases and disorders.

In International Class 005, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at least as early as 06/22/2021, and first used in commerce at least as early as 06/22/2021, and is now in use in such commerce. The applicant is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed goods/services, consisting of a(n) Picture of the product bearing the mark.
Specimen File1
Webpage URL: None Provided
Webpage Date of Access: None Provided

International Class 044:  Collection and preservation of biological tissue, blood and cells; medical diagnostic services; medical treatment services; Providing medical and healthcare information in the field of pharmaceuticals and cell therapy.

In International Class 044, the mark was first used by the applicant or the applicant's related company or licensee or predecessor in interest at least as early as 06/22/2021, and first used in commerce at least as early as 06/22/2021, and is now in use in such commerce. The applicant is submitting one(or more) specimen(s) showing the mark as used in commerce on or in connection with any item in the class of listed goods/services, consisting of a(n) Picture of the product bearing the mark.
Specimen File1
Webpage URL: None Provided
Webpage Date of Access: None Provided

The applicant's current Correspondence Information:

Seragon Pharmaceuticals Inc.

PRIMARY EMAIL FOR CORRESPONDENCE: info@seragonpharm.com       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Michael Hall/   Date: 12/22/2021
Signatory's Name: Michael Hall
Signatory's Position: Duly Authorized Officer
Signatory's Phone Number: 858-366-9100
Signature method: Signed directly within the form
Payment Sale Number: 97185885
Payment Accounting Date: 12/22/2021

Serial Number: 97185885
Internet Transmission Date: Wed Dec 22 19:12:09 ET 2021
TEAS Stamp: USPTO/BAS-XXX.XX.X.XX-202112221912095735
52-97185885-800bcb7f6426d857375176a37619
45093b77fccaa8a86c9b2a67b794c9a33e2-CC-1
2083230-20211222184751712634